| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 14 Feb 2026 | 5 Feb 2026 |
| Quarterly Results Johnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve To consider and approve the Un-Audited Financial Results of the Company for the Quarter ended on 31st December, 2025. This is also to inform that the Trading Window of the Company has been closed from 01st January, 2026 and will remain closed till the completion of 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter ended on 31st December, 2025. 2. Any other agenda, with prior permission of Chairperson. Johnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve With reference to our intimation dated 05th February, 2026 under Regulation 29 of the SEBI (LODR) Regulations, 2015 regarding Board Meeting to be held on Thursday, 12th February ,2026 for approval of Un- Audited Financial Results of the Company for the Quarter ended December 31st, 2025. This is to inform you that due to the unavailability of the auditor, who is currently unable to provide the Limited Review Report , the said Board Meeting has been postponed and rescheduled to be held on Saturday, 14th February, 2026. (As per BSE Announcement dated on: 12.02.2026) UNAUDITED (STANDALONE) FINANCIAL RESULTS The Board of Director have considered and approved the Unaudited (Standalone) Financial Results along with Limited Review Report thereon for the quarter ended on 31st December, 2025. In this regard, please find enclosed herewith the unaudited (Standalone) Financial Results along with Limited Review Report for the quarter ended on 31st December, 2025 pursuant to the Regulation 33 of SEBI (LODR) Regulations, 2015. The copy of the said unaudited (Standalone) quarterly financial results along with copy of Limited Review Report by Statutory auditor of the company is enclosed herewith. (As Per BSE Announcement Dated on:14.02.2026) | ||
| Board Meeting | 13 Feb 2026 | 13 Feb 2026 |
| 1. The Board of Director have considered and approved the appointment of M/S. VRSK & Associates (FRN:011199N) as Statutory Auditor of the Company to fill the casual vacancy w.e.f. 13.02.2026. Consent to act as statutory auditor is annexed. 2. The Board has appointed Ms. Parul Agrawal (DIN: 11268580) as an Additional Non- Executive & Independent Director of the Company w.e.f 13th February, 2026 a brief profile pursuant to SEBI Circular dated CIR/CFD/CMD/4/2015 dated September 09, 2015 is enclosed as (Attached herewith as Annexure) Revised outcome of Meeting of Board of Directors held on Friday 13th Feburay 2026 at Pursuant to Regulation 30 of SEBI LODR Regulation 2015. (As Per BSE Announcement Dated on:17.02.2026) | ||
| Board Meeting | 9 Feb 2026 | 9 Feb 2026 |
| Disclosure as per Regulation 30 of SEBI (LODR) Regulations, 2015 Appointment of Mr. Umesh kumar as an Additional Executive Director of the company. | ||
| Board Meeting | 2 Feb 2026 | 2 Feb 2026 |
| The board has considered and approve the removal of the Corporate Office 1002 10th Floor, Vikram Tower, Rajendra Place, New Delhi-110060., Rajender Nagar, Central Delhi, New Delhi, Delhi, India, 110060. It has been resolved that the Registered Office of the Company shall henceforth also serve as the Corporate Office. This decision has been taken for operational efficiency and better administrative management, and all official communications and business activities shall now be carried out from the Registered Office address. | ||
| Board Meeting | 31 Jan 2026 | 31 Jan 2026 |
| The Board has appointed Ms. Babita (DIN: 09064124) as a Non-Executive & Independent Director of the Company w.e.f 31st January, 2026 a brief profile pursuant to SEBI Circular dated CIR/CFD/CMD/4/2015 dated September 09, 2015 is enclosed as (Attached herewith as Annexure) Further Ms. Babita (DIN: 09064124) is not related to the Directors or Key Managerial Personnel of the Company and is also not debarred from holding the office of Director by virtue of any SEBI order or any other authority. 2. The Board has considered and approved resignation of Mr. Umesh Kumar (DIN: 07015921) as an Additional & Executive Director of the Company w.e.f 31st January, 2026 on account of personal reasons and unavoidable reason. | ||
| Board Meeting | 24 Jan 2026 | 24 Jan 2026 |
| 1. The Board has appointed Mr. Rajender Parsad (DIN: 10871533) as an Additional & Non- Executive Director of the Company w.e.f 24rd January, 2026 a brief profile pursuant to SEBI Circular dated CIR/CFD/CMD/4/2015 dated September 09, 2015 is enclosed as (Attached herewith as Annexure) Further Mr. Rajender Parsad (DIN: 10871533) is not related to the Directors or Key Managerial Personnel of the Company and is also not debarred from holding the office of Director by virtue of any SEBI order or any other authority. 2. The Board has considered and approved resignation of Ms. Babita (DIN: 09064124) Non- Executive & Independent Director of the Company w.e.f 24rd January, 2026 on account of personal reasons and unavoidable reason. | ||
| Board Meeting | 8 Jan 2026 | 8 Jan 2026 |
| Pursuant to the provisions of Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the meeting of the Board of Directors of the Company was held today i.e. Thursday, 08th January, 2026, which commenced at 04:30 P.M. and concluded at 05:00 P.M at the registered office of the Company at Regus Business Center, Privilon building, East Wing, 2nd Floor, Near Iscon cross Road, S.G. Highway, Bodakdev, Ahmedabad, Ahmedabad City, Gujarat, India, 380054 has inter alia, considered and approved the following-: 1. The board has considered and approved the shifting of registered office of the Company from Regus Business Center, Privilon building, East Wing, 2nd Floor, Near Iscon cross Road, S.G. Highway, Bodakdev, Ahmedabad, Ahmedabad City, Gujarat, India, 380054 to Desk No. 491-A, Office No. 4-D, Fourth Floor Vardan Tower, Lakhudi Circle Near Sardar Patel Stadium , Navrangpura, Ahmedabad-380009. Disclosure As Per Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements )Regulation 2015. | ||
| Board Meeting | 24 Nov 2025 | 24 Nov 2025 |
| Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, at its meeting held on 24.11.2025, has approved the following: Establishment of Corporate Office The Board has approved the setting up of a new Corporate Office of the Company at the following address: 1002 10th Floor, Vikram Tower, Rajendra Place, New Delhi-110060. The Corporate Office will support centralised management, administration, and operational functions of the Company. The Board has authorized Umesh Kumar Director to finalize and execute all necessary documents, including lease agreements and related arrangements, and to oversee the setup and operationalization of the office. Pursuant to Regulation 30 of SEBI(LODR) Regulation 2015 we are hereby inform you that the board of director of the company at its meeting held on 24th November has approved the setting up of a new corporate office of the company at the following address : 1002 10th floor, vikram Tower, Rajendra place new delhi 110060 | ||
| Board Meeting | 14 Nov 2025 | 12 Nov 2025 |
| Quarterly Results; Johnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve the Un-Audited Financial Results of the Company for the quarter and half year ended on 30th September 2025. Un-audited financial results for the quarter and half year ended as on 30th September, 2025. (As per BSE Announcement dated on: 14.11.2025) | ||
| Board Meeting | 27 Oct 2025 | 27 Oct 2025 |
| Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e Monday 27th October 2025 at the Registered Office of the Company and transacted the following major business | ||
| Board Meeting | 6 Oct 2025 | 6 Oct 2025 |
| Updation Pursuant to Second proviso to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Updation in Corporate Information on BSE Portal. | ||
| Board Meeting | 23 Jul 2025 | 16 Jul 2025 |
| Johnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2025 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday 23rd July 2025 inter alia to consider following business. - 1.) To approve and take on record the Un-Audited Financial Results of the Company for the first quarter ended on 30th June 2025. 2.) Any other matter with the permission of the board which the Board may think fit. Please take the above intimation in your records. Thanking You. Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Wednesday 23rd July 2025 at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter ended as on 30th June, 2025. The board meeting commented at 01:15 PM and concluded at 01:40 PM Please take the above intimation in your records. Thanking You, PFA (As Per BSE Announcement Dated on: 23.07.2025) | ||
| Board Meeting | 23 May 2025 | 12 May 2025 |
| Johnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 inter alia to consider and approve PFA This is to inform you that Outcome of the Board Meeting of the Company held on Friday 23rd May 2025 in accordance with SEBl (Listing Obligations and Disclosures Requirements) Regulations, 2015, has been approved by the Board of Directors of the Company and taken on record inter-alia the following items; 1.) Consideration and Approval of Audited Financial Result for the Year ended 31st March, 2025. 2.) Independent Audit Report in pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 for the F.Y. 31st March, 2025. Further, we hereby declare that the Auditor of the Company has issued the Audit report under the Companies Act, 2013 and financial results as prepared under SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 for the financial year ended on March 31, 2025 with Unmodified opinion. The board meeting commenced on 05:40 PM and concluded on 06:10 PM. Request you to kindly take on record the same. Thanking You. (As Per BSE Announcement Dated on :23.05.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
